11Mês·

Vertex forecasts sales growth of 8-9% by 2025 as the renal pipeline accelerates

$VRTX (+1,59%) I remain invested here too.


Financial results


Wagner reported: "Combined non-GAAP R&D, R&D and SG&A expenses were $1.28 billion in the third quarter of 2025, compared to $1.08 billion in the third quarter of 2024."


He explained: "Adjusted earnings per share (non-GAAP) in the third quarter of 2025 were $4.80, an increase of 10% compared to $4.38 in the third quarter of 2024."


Vertex ended the third quarter with cash and investments totaling $12 billion after repurchasing more than 2.7 million shares for approximately $1.1 billion.


Outlook under the link ⬇️


https://seekingalpha.com/news/4513825-vertex-signals-8-9-percent-2025-revenue-growth-as-renal-pipeline-accelerates-and-alyftrek

attachment
8
Participar na conversa